By welcoming Mr. Kawaoto, HACARUS aims to further promote R&D and sales efforts for AI powered drug discovery.
April 22, 2021 – Kyoto, Japan – HACARUS, the leading provider of lightweight and explainable AI, today announced that Satoshi Kawaoto was appointed as Outside Audit & Supervisory Board Member at the general shareholders meeting held on March 31, 2021.
Since its founding in 2014, contributing to the medical and drug discovery fields has been one of HACARUS’ main aims. With the addition of Mr. Kawaoto, who has a strong track record of executive management at pharmaceutical companies, HACARUS aims to further promote R&D and commercialization efforts of drug discovery initiatives, using its award-winning AI technology.
HACARUS INC, founded 2014 in Kyoto, Japan is the leading provider of Explainable Lightweight AI Tools, backed by Osaka Gas and Miyako Capital (Kyoto University) among others. Its solutions are used in the Medical field to enable humans to make better, faster and more reliable decisions, based on AI driven insights. Hacarus’ proprietary AI engine is built using Sparse Modeling, an AI method that understands data like a human would – by its unique key features and is far more resource, time and energy efficient when compared to Deep Learning. To learn more, visit https://hacarus.com